Understanding how anti-VEGF helps close leaky blood vessels
Anti-VEGF-mediated barrier closure
This study is looking at how a treatment called anti-VEGF can help fix leaky blood vessels in people with conditions like diabetic retinopathy and macular edema, aiming to improve their vision and overall quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10909222 on NIH RePORTER |
What this research studies
This research investigates the effects of anti-VEGF treatment on blood vessels that leak due to chronic exposure to vascular endothelial growth factor (VEGF). By analyzing gene expression changes in endothelial cells, the study aims to uncover how anti-VEGF can restore the integrity of these blood vessels. Patients with conditions like proliferative diabetic retinopathy and diabetic macular edema may benefit from this research, as it seeks to improve their quality of life by addressing the underlying mechanisms of blood vessel leakage. The methodology includes RNA sequencing to identify genes affected by anti-VEGF treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with proliferative diabetic retinopathy, diabetic macular edema, or neovascular age-related macular degeneration.
Not a fit: Patients with conditions unrelated to blood vessel leakage or those not affected by VEGF-related diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients suffering from vision-threatening conditions caused by leaky blood vessels.
How similar studies have performed: Previous research has shown that anti-VEGF treatments can effectively reduce blood vessel leakage, indicating a promising avenue for further exploration.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kazlauskas, Andrius — University of Illinois at Chicago
- Study coordinator: Kazlauskas, Andrius
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.